Monkeypox Virus–Associated Severe Proctitis Treated With Oral Tecovirimat: A Report of Two Cases

Lucar, Jose; Roberts, Afsoon D.; Saardi, Karl M.; Yee, Rebecca; Siegel, Marc; Palmore, Tara N.

doi:10.7326/l22-0300

Cited by 38 publications

(41 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…308 Moreover, several reports have also documented the efficacy and safety of tecovirimat in the treatment of monkeypox. 308,[330][331][332] Healthcare providers can now provide tecovirimat treatment to monkeypox patients under an expanded access Investigational New Drug (EA-IND) protocol developed by CDC and FDA. A total of 1001 cases receiving this antiviral drug have been documented, in addition, data was abstracted by the Centers for Disease Control.…”

Section: Treatmentmentioning

confidence: 99%

Monkeypox: epidemiology, pathogenesis, treatment and prevention

Huang

Wang

2022

Sig Transduct Target Ther

165

120

View full text Add to dashboard Cite

Monkeypox is a zoonotic disease that was once endemic in west and central Africa caused by monkeypox virus. However, cases recently have been confirmed in many nonendemic countries outside of Africa. WHO declared the ongoing monkeypox outbreak to be a public health emergency of international concern on July 23, 2022, in the context of the COVID-19 pandemic. The rapidly increasing number of confirmed cases could pose a threat to the international community. Here, we review the epidemiology of monkeypox, monkeypox virus reservoirs, novel transmission patterns, mutations and mechanisms of viral infection, clinical characteristics, laboratory diagnosis and treatment measures. In addition, strategies for the prevention, such as vaccination of smallpox vaccine, is also included. Current epidemiological data indicate that high frequency of human-to-human transmission could lead to further outbreaks, especially among men who have sex with men. The development of antiviral drugs and vaccines against monkeypox virus is urgently needed, despite some therapeutic effects of currently used drugs in the clinic. We provide useful information to improve the understanding of monkeypox virus and give guidance for the government and relative agency to prevent and control the further spread of monkeypox virus.

show abstract

Section: Treatmentmentioning

confidence: 99%

Monkeypox: epidemiology, pathogenesis, treatment and prevention

Huang

Wang

2022

Sig Transduct Target Ther

165

120

View full text Add to dashboard Cite

show abstract

“…Traditionally, monkeypox lesions have been limited to the skin; however, during the present outbreak, affected patients have increasingly reported proctitis, a manifestation not commonly observed with monkeypox in previous years [34]. According to several reports, proctitis could be present in approximately 14% of the patients; however, its frequency has been reported to be as high as 25% in Spain [35], and it could be even the initial symptom in affected people [36][37][38]. We believe that it is crucial for clinicians to be aware of monkeypox proctitis to assure the proper identi cation, treatment, and isolation of cases, with the ultimate goal of limiting the spread of this disease.…”

Section: Discussionmentioning

confidence: 99%

Level of Knowledge regarding Monkeypox among Peruvian Physicians during the 2022 Outbreak: A Cross-Sectional Study

Zamora

Soriano-Moreno

et al. 2022

Preprint

View full text Add to dashboard Cite

Introduction: Monkeypox has become a public health emergency given the rapid spread of the disease worldwide. Due to the high incidence of this disease in Peru and the poor knowledge about monkeypox among healthcare workers in non-endemic countries, it is crucial to determine the knowledge status of Peruvian physicians. Methodology: We conducted an analytical cross-sectional study based on an online survey from August to September 2022. Physicians who had a medical license and lived and practiced Medicine in Peru were included. To evaluate the factors associated with a higher level of knowledge, we used crude (cPR) and adjusted (aPR) prevalence ratios with 95% confidence intervals (95% CI) using Poisson regression. Results We included 463 physicians. The mean age was 36.6 (SD: 10.3) years, and most were male (58.1%). Regarding knowledge, the median knowledge score was 14 [IQR: 13 to 15] out of 17 points. In terms of knowledge gaps, only 60.7% of the participants knew that there was an FDA-approved vaccine for monkeypox, 49.0% of participants knew about monkeypox proctitis and 33.3% acknowledged that it could be transmitted by the bite of an infected rodent. We found that taking care of patients with monkeypox (aPR: 1.39; 95% CI: 1.13 to 1.72) was associated with a higher knowledge (> p50) while living in the jungle (aPR: 0.61; 95% CI: 0.41 to 0.91) was associated with lower knowledge (< p50). Conclusions Our study showed a high level of knowledge about monkeypox among Peruvian physicians. However, educational campaigns may be necessary, especially for physicians from the jungle and those who do not have clinical experience in monkeypox.

show abstract

“…He responded well to tecovirimat, which at the time of his presentation required CDC approval. Given rapid improvement with treatment, also anecdotally reported in other settings, 8 we recommend considering treatment early to hopefully alleviate symptoms and prevent progression, while awaiting results of more conclusive trials.…”

Section: Discussionmentioning

confidence: 99%